Yahoo Finance
(NASDAQ:MRNA) proposed a private placement of $2.0 billion in convertible senior notes due in 2032, with an option for initial purchasers to acquire another $300 million.
The notes would be senior unsecured obligations, carry no regular interest, and have no principal accretion.
Net proceeds would pay for capped-call transactions and support general corporate purposes, which may include oncology investment and debt repayment.
Final terms, including the initial conversion rate, remain subject to pricing.
(NASDAQ:MRNA) could settle in cash, common shares, or a combination of both.
The ultimate economics will depend on the conversion premium, hedge cost, and equity value when holders convert.
The strongest feature is cash preservation.
With no regular coupon, the proposed financing would give Moderna, Inc.
(NASDAQ:MRNA) access to substantial capital without requiring regular cash interest payments.
That structure can extend strategic flexibility while oncology programs advance toward possible regulatory filings and launches.
The timing follows company-reported positive topline Phase 3 results for intismeran autogene in combination with pembrolizumab in adjuvant melanoma.
The study met its primary endpoint of recurrence-free survival and secondary endpoint of distant metastasis-free survival.
| Product | Price | Change |
|---|---|---|
| Brent Crude | $102.14/bbl | +0.34% |
| WTI Crude | $96.90/bbl | +0.21% |
| EN590 Diesel | $846/MT | +0.18% |
| Jet Fuel A-1 | $1090/MT | +0.55% |
| Mazut M100 | $450/MT | -0.15% |
| Bitumen 60/70 | $470/MT | +0.08% |
| Sulphur Gran 99.5% | $470/MT | -0.44% |
| Urea 46% Gran | $650/MT | +1.12% |
| NPK 16-16-16 | $460/MT | -0.28% |
| Nat Gas TTF | $15.42/MMBtu | +0.92% |
Comments
Post a Comment